Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6806052 | 1.00 | TUBB1 (0.47) | TUBB1USP2MAPTL3MBTL1NPSR1 | |
| SCHEMBL6688280 | 0.92 | TUBB1 (0.39) | TUBB1USP2L3MBTL1 | |
| SCHEMBL6805382 | 0.86 | TUBB1 (0.59) | TUBB1MMP1MMP2MMP3 | |
| SCHEMBL6672740 | 0.85 | TUBB1 (0.44) | TUBB1USP2MAPTL3MBTL1NPSR1 | |
| SCHEMBL6670110 | 0.85 | TUBB1 (0.44) | TUBB1USP2MAPTL3MBTL1NPSR1 | |
| SCHEMBL6806060 | 0.85 | TUBB1 (0.44) | TUBB1USP2MAPTL3MBTL1NPSR1 | |
| SCHEMBL6806057 | 0.85 | TUBB1 (0.44) | TUBB1USP2MAPTL3MBTL1NPSR1 | |
| SCHEMBL6672739 | 0.85 | TUBB1 (0.44) | TUBB1USP2MAPTL3MBTL1NPSR1 | |
| SCHEMBL6672986 | 0.83 | TUBB1 (0.54) | TUBB1USP2MAPT | |
| SCHEMBL6675854 | 0.82 | TUBB1 (0.40) | TUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040121965-A1 | Method of treating resistant tumors | WYETH HOLDINGS CORPORATION (US) | 2004-06-24 | — | — | US | disclosed |
| WO-2004026293-A2 | HEMIASTERLIN DERIVATIVES FOR TREATING RESISTANT TUMORS | WYETH HOLDINGS CORPORATION (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121965-A1 | Method of treating resistant tumors | SLC11A2, VHL, REN | TUBB1 199/4885USP2 1679/4885MAPT 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.